REPLY
Authors' response to letter to the editor regarding relationship between sodium-glucose cotransporter two inhibitors and atrial fibrillation recurrence after pulmonary vein isolation in patients with type 2 diabetes and persistent atrial fibrillation
Dan Qi MD,
Dan Qi MD
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Search for more papers by this author Xiaonan Guan MD,
Xiaonan Guan MD
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Search for more papers by this author Jianjun Zhang PhD,
Corresponding Author
Jianjun Zhang PhD
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Correspondence Jianjun Zhang, PhD, Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Email: [email protected]
Search for more papers by this author
Dan Qi MD,
Dan Qi MD
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Search for more papers by this author Xiaonan Guan MD,
Xiaonan Guan MD
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Search for more papers by this author Jianjun Zhang PhD,
Corresponding Author
Jianjun Zhang PhD
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Correspondence Jianjun Zhang, PhD, Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Email: [email protected]
Search for more papers by this author
First published: 19 August 2024
No abstract is available for this article.
REFERENCES
- 1Qi D, Guan X, Liu X, Liu L, Liu Z, Zhang J. Relationship between sodium-glucose cotransporter 2 inhibitors and atrial fibrillation recurrence after pulmonary vein isolation in patients with type 2 diabetes and persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2024; 35: 1799-1805. doi:10.1111/jce.16369
- 2Oral H, Knight BP, Özaydın M, et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol. 2002; 40(1): 100-104. doi:10.1016/s0735-1097(02)01939-3
- 3Noujaim C, Lim C, Donnellan E, et al. Smartphone AF burden during the blanking period predicts catheter ablation outcomes. JACC Clin Electrophysiol. 2023; 9(10): 2085-2095. doi:10.1016/j.jacep.2023.06.010
- 4Pokushalov E, Romanov A, Corbucci G, et al. Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? Heart Rhythm. 2012; 9(9): 1375-1379. doi:10.1016/j.hrthm.2012.03.047
- 5Shao Q, Meng L, Lee S, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019; 18(1): 165. doi:10.1186/s12933-019-0964-4
- 6Shiina K, Tomiyama H, Tanaka A, et al. Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial. Hypertension Res. 2023; 46(2): 495-506. doi:10.1038/s41440-022-01085-x
